The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Lauren Averett Byers, M.D., professor of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, has received the 2025 Edith and Peter O’Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST). The award recognizes her fundamental discoveries and contributions to identifying novel therapeutic strategies for small cell lung cancer (SCLC), which have paved the way for personalized treatments, even in the most highly recalcitrant cancers.
MD Anderson and AmMax Bio announced agreements to develop and advance AmMax's AMB-066 monoclonal antibody therapy for colorectal cancer with minimal residual disease.
Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual Meeting content from MD Anderson can be found at MDAnderson.org/ASH.
Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This special edition features upcoming oral presentations by MD Anderson researchers at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, providing new insights and advances in hematological malignancies and diseases. All ASH content from MD Anderson can be found at MDAnderson.org/ASH.
Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at The University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
The University of Texas MD Anderson Cancer Center today was awarded nearly $8 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of faculty recruitment as well as lung and colorectal cancer screening and early detection programs to address cancer incidence rates across Texas.
A new study from researchers at The University of Texas MD Anderson Cancer Center finds that, in healthy women, some breast cells that otherwise appear normal may contain chromosome abnormalities typically associated with invasive breast cancer. The findings question conventional thinking on the genetic origins of breast cancer, which could influence early cancer detection methods. The study, published today in Nature, discovered that at least 3% of normal cells from breast tissue in 49 healthy women contain a gain or loss of chromosomes, a condition known as aneuploidy, and that they expand and accumulate with age. This poses questions for our understanding of “normal” tissues, according to principal investigator Nicholas Navin, Ph.D., chair of Systems Biology.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon longstanding MD Anderson clinical and research expertise to lead the world in developing and advancing impactful cell therapies for patients in need.
The University of Texas MD Anderson Cancer Center today honored Tiffany Richards, Ph.D., A.P.R.N., A.N.P.-B.C., A.O.C.N.P., with the 2024 Brown Foundation Award for Excellence in Oncology Nursing.
The University of Texas MD Anderson Cancer Center today announced the selection of Jennifer Bickel, M.D., as the institution’s inaugural vice president and chief wellness officer (CWO). She will begin on January 6, 2025. Working closely with the senior vice president of people, culture and infrastructure, as well as the chief academic officer, she will spearhead initiatives that prioritize employee well-being, professional fulfillment and community resilience.
Smokers who are diagnosed with cancer now have more incentive to quit, as researchers from The University of Texas MD Anderson Cancer Center have found survival outcomes were optimized when patients quit smoking within six months of their diagnosis.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC).
As part of its ongoing commitment to patient comfort and healing, The University of Texas MD Anderson Cancer Center today announced a new focus on art to support the revitalization and expansion of its clinical facilities. This initiative will include the creation of a multisensory healing environment in both public spaces and patient care areas that are designed to prevent disease, promote health and foster well-being.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its second annual scientific symposium on Oct. 10. The symposium, with more than 900 attendees, featured two Nobel laureates and a $5 million gift from the David and Eula Wintermann Foundation to advance the work of the Allison Institute.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right